DALLAS, Aug. 5, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc. (Nasdaq:ARIA). The report includes financial, comparative and investment analyses and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/ARIA
The MACD for ARIA currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9day moving average. Second, the MACD is above 0 which implies that the underlying moving averages are trending higher.
ARIAD Pharmaceuticals Inc. (ARIA) focuses on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. The Company's lead cancer product candidate, ridaforolimus, is an internally discovered, potent inhibitor of the protein mTOR that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival. Its second product candidate, AP24534, an investigational, pan BCR-ABL inhibitor, has potential applications in various hematological cancers and solid tumors and is wholly owned by the Company. Its third product candidate, AP26113, is an investigational anaplastic lymphoma kinase (ALK), inhibitor that has the potential to regulate multiple cancer pathways and to be used in the treatment of certain patients with various cancers, including non-small cell lung cancer, lymphoma and neuroblastoma.
Message Board Search for ARIA: http://www.boardcentral.com/boards/ARIA
In the report, the analyst notes:
"For the quarter ended June 30, 2010, the Company reported net income of $159.3 million, or $1.35 per share on a diluted basis, compared to a net loss of $21.0 million, or $0.24 per share, for the same period in 2009. For the six-month period ended June 30, 2010, the Company reported net income of $136.0 million, or $1.22 per share on a diluted basis, compared to a net loss of $41.2 million, or $0.50 per share for the same period in 2009.
"ARIA recently announced updated clinical data from an ongoing phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor …"
To read the entire report visit: http://www.microstockprofit.com/lp/ARIA
See what investors are saying about ARIA at penny stock forum
Get breaking news on ARIA at http://thestockmarketwatch.com/
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.